Recent Updates
Recently added Catalysts

Hydrochlorothiazide

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 24, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

Clinical trial landscape

Hydrochlorothiazide · 1 trial · 1 indication

Early Phase 1 1
NCT00649324Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mgHealthy
COMPLETED40 Analytics
EARLY_PHASE1COMPLETED
Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Bioequivalence
within 30 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
1EXPERIMENTALHydrochlorothiazide Tablets 50 mg
2ACTIVE_COMPARATORHydrochlorothiazide Tablets 50 mg

Interventions

NameTypeDescription
Hydrochlorothiazide Tablets 50 mgDRUG50mg, single dose fasting
Hydrochlorothiazide Tablets (50 mgDRUG50mg, single dose fasting
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female a. Women of childbearing potential must have a negative serum (β-HCG) pregnancy test performed within 21 days prior to the start of the study and on the evening prior to each dose administration. I...

Countries:United States
Unlock Eligibility Criteria